Delcath Systems (NASDAQ:DCTH – Get Free Report) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Monday,Zacks.com reports.
Several other research firms have also weighed in on DCTH. Wall Street Zen lowered shares of Delcath Systems from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Weiss Ratings raised Delcath Systems from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday. BTIG Research dropped their target price on Delcath Systems from $23.00 to $19.00 and set a “buy” rating on the stock in a research report on Thursday, February 26th. Finally, Evercore set a $27.00 price objective on shares of Delcath Systems in a research report on Thursday, February 26th. Five analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $22.50.
Read Our Latest Analysis on Delcath Systems
Delcath Systems Trading Up 2.5%
Delcath Systems (NASDAQ:DCTH – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.07. The company had revenue of $24.99 million for the quarter, compared to the consensus estimate of $23.51 million. Delcath Systems had a return on equity of 0.51% and a net margin of 0.62%. As a group, equities analysts predict that Delcath Systems will post -0.88 EPS for the current fiscal year.
Institutional Investors Weigh In On Delcath Systems
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Allspring Global Investments Holdings LLC purchased a new position in Delcath Systems during the first quarter valued at $306,000. XTX Topco Ltd increased its holdings in shares of Delcath Systems by 339.4% during the fourth quarter. XTX Topco Ltd now owns 71,193 shares of the company’s stock valued at $719,000 after acquiring an additional 54,990 shares in the last quarter. Millennium Management LLC raised its position in shares of Delcath Systems by 3.0% in the 4th quarter. Millennium Management LLC now owns 246,444 shares of the company’s stock worth $2,489,000 after purchasing an additional 7,190 shares during the last quarter. Man Group plc raised its position in shares of Delcath Systems by 34.1% in the 4th quarter. Man Group plc now owns 38,158 shares of the company’s stock worth $385,000 after purchasing an additional 9,705 shares during the last quarter. Finally, Balyasny Asset Management L.P. boosted its stake in Delcath Systems by 69.5% in the 4th quarter. Balyasny Asset Management L.P. now owns 52,140 shares of the company’s stock worth $527,000 after purchasing an additional 21,384 shares in the last quarter. Hedge funds and other institutional investors own 61.12% of the company’s stock.
About Delcath Systems
Delcath Systems, Inc is a specialty pharmaceutical and medical technology company focused on the development and commercialization of its proprietary Hepatic CHEMOSAT® Delivery System, designed to deliver high-dose chemotherapeutic agents directly to the liver while minimizing systemic exposure. The company’s core technology performs isolated hepatic perfusion, enabling oncologists to administer concentrated melphalan to patients with primary and metastatic liver tumors, including those arising from ocular melanoma.
Featured Articles
- Five stocks we like better than Delcath Systems
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
